Roche Venture Fund appeared to be the VC, which was created in 2002. The main office of represented VC is situated in the Basel. The venture was found in Europe in Switzerland. Roche Venture Fund appeared to be a CVC structure as part of the corporation.
For fund there is no match between the location of its establishment and the land of its numerous investments - United States. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight AveXis, Foundation Medicine, Alios BioPharma. Among the most popular fund investment industries, there are Pharmaceutical, Therapeutics. The fund has no exact preference in a number of founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low.
We also calculated 3 valuable employees in our database.
The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the Roche Venture Fund, startups are often financed by SR One, Apple Tree Partners, Pfizer Venture Investments. The meaningful sponsors for the fund in investment in the same round are 5AM Ventures, Lilly Ventures, Ysios Capital. In the next rounds fund is usually obtained by SR One, Pfizer Venture Investments, Lilly Ventures.
Speaking about the real fund results, this VC is 10 percentage points less often commits exit comparing to other organizations. The usual things for fund are deals in the range of 10 - 50 millions dollars. Comparing to the other companies, this Roche Venture Fund performs on 4 percentage points less the average number of lead investments. The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. The fund is constantly included in 2-6 deals per year. The increased amount of exits for fund were in 2017.
Related Funds
| Fund Name | Location |
| A-Labs Advisory & Finance | HaMerkaz, Israel, Kadima |
| AfterWork Ventures | - |
| Capital for Enterprise | England, Sheffield, United Kingdom |
| Hengqin Zanlu Equity Investment Fund | - |
| Hua Partners | China, Guangdong, Shenzhen |
| Jetty Ventures | Central, Central Region, Singapore |
| Kakao Pay | Cheju-do, Jeju, South Korea |
| Manresa Partners | England, London, United Kingdom |
| MetaProp NYC | New York, New York, United States |
| Monstar Lab | Japan, Tokyo |
| New Asia Partners | - |
| Ningbo Xuri Lamp Decoration | China, Xiangshan, Zhejiang |
| Ontario Scale-Up Vouchers Program (OSVP) | - |
| RAJ Capital | California, Newport Beach, United States |
| Salvia GmbH | Bayern, Germany, Holzkirchen |
| Spectrum Assets | Connecticut, Stamford, United States |
| Twenty Ten Capital | England, London, United Kingdom |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Cour Pharmaceuticals Development | $105M | 30 Jan 2024 | Elmhurst, Illinois, United States | ||
GlycoEra | 05 Jan 2024 | Schlieren, Zurich, Switzerland | |||
NMD Pharma | $88M | 15 Nov 2023 | Aarhus, Central Denmark Region, Denmark | ||
Mironid | $42M | 13 Sep 2023 | United Kingdom, Scotland, United Kingdom | ||
DiogenX | $39M | 10 May 2023 | Marseille, Provence-Alpes-Côte d'Azur, France | ||
Bonum Therapeutics | $93M | 15 Nov 2022 | Seattle, Washington, United States | ||
Good Therapeutics | $8M | 30 Dec 2021 | Seattle, Washington, United States | ||
GlycoEra | $49M | 05 Nov 2021 | Schlieren, Zurich, Switzerland | ||
| $42M | 17 May 2021 | San Francisco, California, United States |
– Soteria Biotherapeutics, Inc. is a San Francisco, CA-based immuno-oncology company focused on developing a next generation of switchable bispecific T-cell engagers to treat patients with solid tumor cancers.
– The company raised $42m in Series A financing.
– The round was led by Roche Venture Fund and 5AM Ventures with participation from other leading investors, including M Ventures, Novartis Venture Fund and Alexandria Venture Investments.
– The company intends to use the funds for advancement of its technology and build a pipeline of T-LITE development candidates with potential in well validated cancer targets.
– Arch Oncology, a clinical-stage immuno-oncology company, has closed a $105m Series C financing co-led by Eventide Asset Management, Cowen Healthcare Investments and current investor 3×5 Partners.
– New investors in the round included Adage Capital Management, Point72 Asset Management, Avego Healthcare Capital, FMB Research and Broadfin Holdings.
– The company’s existing investors, including Roche Venture Fund, RiverVest Venture Partners, and Lightchain also participated in the round.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Cour Pharmaceuticals Development | $105M | 30 Jan 2024 | Elmhurst, Illinois, United States | ||
GlycoEra | 05 Jan 2024 | Schlieren, Zurich, Switzerland | |||
NMD Pharma | $88M | 15 Nov 2023 | Aarhus, Central Denmark Region, Denmark | ||
Mironid | $42M | 13 Sep 2023 | United Kingdom, Scotland, United Kingdom | ||
DiogenX | $39M | 10 May 2023 | Marseille, Provence-Alpes-Côte d'Azur, France | ||
Bonum Therapeutics | $93M | 15 Nov 2022 | Seattle, Washington, United States | ||
Good Therapeutics | $8M | 30 Dec 2021 | Seattle, Washington, United States | ||
GlycoEra | $49M | 05 Nov 2021 | Schlieren, Zurich, Switzerland | ||
| $42M | 17 May 2021 | San Francisco, California, United States |
